Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2020-08-13 Investor Presentation
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Investor Presentation 2020
Investor Presentation Classification · 99% confidence The document is titled 'Biotest AG Company Presentation H1 2020 August 2020'. It contains key financial highlights for the first half of 2020 (H1 2020), including sales, EBIT figures, and forward-looking guidance. It also heavily features updates on product development, clinical trials (Phase II and III studies for COVID-19 related treatments like Trimodulin), and market analysis. This structure—a presentation summarizing interim financial results, operational updates, and pipeline progress—is characteristic of an Investor Presentation (IP). It is not a full regulatory report (like 10-K or IR) nor a brief earnings release (ER), but a detailed presentation deck.
2020-08-13 German
Investor Presentation 2020
Investor Presentation Classification · 99% confidence The document is titled 'Biotest AG Company Presentation H1 2020 August 2020'. It contains key financial highlights for the first half of 2020 (H1 2020), including sales, EBIT figures, and forward-looking guidance. It also heavily features updates on product development, clinical trials (Phase II and III studies for COVID-19 related treatments like Trimodulin), and market analysis. This structure—a presentation summarizing interim financial results, operational updates, and pipeline progress—is characteristic of an Investor Presentation (IP). It is not a full regulatory report (like 10-K or IR) nor a brief earnings release (ER), but a detailed presentation deck.
2020-08-13 English
Half-yearly financial report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Report 2020' for Biotest AG. It contains comprehensive financial data, including a consolidated statement of income, balance sheet, cash flow statement, and an interim management report for the period ending 30 June 2020. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2020
2020-08-13 English
Halbjahresfinanzbericht 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresbericht' (Half-Year Report) for Biotest AG for the first half of 2020. It contains comprehensive financial data, including a balance sheet, income statement, cash flow statement, and management discussion and analysis (Konzernzwischenlagebericht). It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2020
2020-08-13 German
Datum:03.08.2020
AGM Information Classification · 100% confidence The document is a formal announcement regarding the appropriation of profit (Gewinnverwendungsbeschluss) following the Annual General Meeting of Biotest AG. It specifies the dividend amount per share and the allocation of the balance sheet profit for the 2019 fiscal year. Since it specifically details the dividend payout amounts and payment structure, it falls under the 'Notice of Dividend Amount' category.
2020-08-03 German
Biotest AG: Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020
Regulatory Filings Classification · 99% confidence The document is a press release dated July 21, 2020, announcing research updates ('promising data on next generation recombinant Factor VIII') presented at a scientific congress (ISTH 2020). It details scientific findings, product potential (HAT and HAT RI), and mentions exploring partnering options. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is an announcement of research progress and business development news, and it doesn't fit the specific categories like DIV, CAP, or MANG, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for corporate news releases that are not otherwise classified, especially when disseminated via services like DGAP.
2020-07-21 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.